Transthyretin Cardiac Amyloidosis Clinical Trial
Official title:
Valeur Pronostique Dans Une Population d'Amylose Cardiaque Des paramètres échocardiographiques basée Sur Une Approche d'Apprentissage Automatique
Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and imaging. Still currently incurable, the evolution of this pathology is burdened by numerous comorbidities, including iterative hospitalizations for heart failure leading to death. The Machine Learning approach has already shown its efficiency in terms of diagnosis but its prognostic approach has not yet been studied.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06257485 -
Bronx Transthyretin Amyloid Cardiomyopathy Database
|
||
| Completed |
NCT05064839 -
Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)
|
Phase 3 | |
| Recruiting |
NCT05797857 -
Exercise Training in Transthyretin Cardiac Amyloidosis
|
N/A | |
| Recruiting |
NCT05489523 -
Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation
|
Phase 4 | |
| Recruiting |
NCT04899180 -
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
|
Early Phase 1 | |
| Recruiting |
NCT06328075 -
Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis
|
||
| Recruiting |
NCT04276220 -
Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery
|
N/A |